|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 199.96 USD | -0.82% |
|
-2.66% | +38.27% |
| 10/12 | Fda probes if Covid shots might be linked to deaths of adults - Bloomberg News | RE |
| 09/12 | Johnson & Johnson Says Tecvayli With Darzalex Faspro Cuts Risk of Death in Multiple Myeloma | MT |
| Capitalization | 48TCr 41TCr 39TCr 36TCr 67TCr 43,28700Cr 72TCr 4,50300Cr 1,75000Cr 20,51700Cr 1,80800Cr 1,77000Cr 75,59400Cr | P/E ratio 2025 * |
19.2x | P/E ratio 2026 * | 21.2x |
|---|---|---|---|---|---|
| Enterprise value | 50TCr 43TCr 40TCr 38TCr 69TCr 45,13000Cr 76TCr 4,69500Cr 1,82500Cr 21,39100Cr 1,88500Cr 1,84500Cr 78,81300Cr | EV / Sales 2025 * |
5.36x | EV / Sales 2026 * | 5.03x |
| Free-Float |
77.08% | Yield 2025 * |
2.56% | Yield 2026 * | 2.65% |
Last Transcript: Johnson & Johnson
| 1 day | -0.82% | ||
| 1 week | -2.66% | ||
| Current month | -3.36% | ||
| 1 month | +7.18% | ||
| 3 months | +13.00% | ||
| 6 months | +28.82% | ||
| Current year | +38.27% |
| 1 week | 199.9 |  | 205.54 |
| 1 month | 189.05 | | 207.81 |
| Current year | 140.68 | | 207.81 |
| 1 year | 140.68 | | 207.81 |
| 3 years | 140.68 | | 207.81 |
| 5 years | 140.68 | | 207.81 |
| 10 years | 94.28 | | 207.81 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 62 | 03/01/2022 |
Joseph Wolk
DFI | Director of Finance/CFO | 58 | 01/07/2018 |
Penny M. Heaton
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Anne Mulcahy
BRD | Director/Board Member | 72 | 23/10/2009 |
Mark McClellan
BRD | Director/Board Member | 61 | 15/10/2013 |
Mary Beckerle
BRD | Director/Board Member | 70 | 09/06/2015 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 14.01% | 303 M€ | -22.24% | - |
| 12.91% | 26 M€ | +11.25% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.82% | -2.66% | +33.66% | +13.78% | 49TCr | |
| -1.54% | -6.11% | +22.23% | +172.09% | 89TCr | |
| -0.06% | -0.62% | +26.29% | +36.75% | 39TCr | |
| -0.76% | +0.64% | +22.59% | +3.51% | 34TCr | |
| +0.10% | -1.51% | +27.00% | +19.71% | 28TCr | |
| +0.17% | +0.58% | +19.51% | +24.96% | 25TCr | |
| -2.06% | -4.10% | -6.65% | -10.93% | 25TCr | |
| +0.07% | -2.56% | -61.75% | -35.08% | 21TCr | |
| -2.30% | -7.24% | +13.05% | +12.63% | 17TCr | |
| -1.51% | -3.67% | +31.76% | +35.68% | 15TCr | |
| Average | -1.00% | -2.57% | +12.77% | +27.31% | 34.19TCr | |
| Weighted average by Cap. | -1.08% | -2.84% | +17.35% | +54.27% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 9.38TCr 8.06TCr 7.56TCr 7.04TCr 13TCr 8,42400Cr 14TCr 88TCr 34TCr 3,99300Cr 35TCr 34TCr 14,71100Cr | 9.84TCr 8.46TCr 7.93TCr 7.39TCr 14TCr 8,84500Cr 15TCr 92TCr 36TCr 4,19200Cr 37TCr 36TCr 15,44600Cr |
| Net income | 2.48TCr 2.13TCr 2TCr 1.86TCr 3.43TCr 2,22600Cr 3.72TCr 23TCr 9TCr 1,05500Cr 9.3TCr 9.1TCr 3,88800Cr | 2.24TCr 1.92TCr 1.81TCr 1.68TCr 3.1TCr 2,01300Cr 3.37TCr 21TCr 8.14TCr 95TCr 8.41TCr 8.23TCr 3,51500Cr |
| Net Debt | 2.05TCr 1.76TCr 1.65TCr 1.54TCr 2.84TCr 1,84300Cr 3.08TCr 19TCr 7.45TCr 87TCr 7.7TCr 7.54TCr 3,21900Cr | 1.34TCr 1.15TCr 1.08TCr 1.01TCr 1.86TCr 1,20600Cr 2.02TCr 13TCr 4.87TCr 57TCr 5.03TCr 4.93TCr 2,10500Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/25/09 | 199.96 $ | -0.82% | 73,61,835 |
| 08/25/08 | 201.62 $ | -0.15% | 77,85,708 |
| 05/25/05 | 201.93 $ | -0.27% | 77,85,552 |
| 04/25/04 | 202.48 $ | -1.39% | 90,49,943 |
| 03/25/03 | 205.33 $ | -0.04% | 83,63,292 |
Delayed Quote Nyse, December 10, 2025 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JNJ Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition